Solventum vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (76 vs 80)
Solventum logo

Solventum

LeaderHealthcare Tech

Medical Technology

Solventum (SOLV) reported ~$8.2B revenue in FY2024. Medical technology company spun off from 3M in 2024, providing wound care, oral care, healthcare IT, and purification products. HQ: Maplewood, MN.

AI VisibilityBeta
Overall Score
B76
Category Rank
#72 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
77
Perplexity
78
Gemini
71

About

Solventum Corporation is a global medical technology company spun off from 3M Company in April 2024, combining 3M's Health Care segment into an independent publicly traded entity. The company operates four business segments: MedSurg (wound management, surgical solutions), Dental Solutions (3M/Solventum brand dental products), Health Information Systems (clinical documentation and coding software), and Purification & Filtration (membrane filtration for pharmaceuticals and food/beverage). The spinoff created a focused MedTech company with $8+ billion in revenue and operations in over 70 countries.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

76
Overall Score
80
#72
Category Rank
#18
81
AI Consensus
83
stable
Trend
stable
77
ChatGPT
78
78
Perplexity
78
71
Gemini
80
73
Claude
84
72
Grok
77

Key Details

Category
Medical Technology
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Solventum
Medical Technology

Integrations

Only Solventum
Only Bristol Myers Squibb
Solventum is classified as company. Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.